As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck...
- Merck initiates three Phase III trials into Keytruda for prostate cancer
- SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe
- Erectile dysfunction: giving patients more choice and better treatments
- AbCellera and Novartis enter into multi-target partnership
- National Heart Month: how can you heal a broken heart?
FDA accepts Sarepta’s NDA for precision medicine Golodirsen
US precision medicine company Sarepta Therapeutics has announced the US Food and Drug Administration (FDA) has accepted its new drug application (NDA) for its Duchenne muscular dystrophy (DMD) drug Golodirsen (SRP-4053).
The world is getting better, look no further than vaccines
GlobalData believes that the V920 vaccine is likely to be approved by the FDA this year and will establish a market-leading position in Ebola prevention.
Merck initiates three Phase III trials into Keytruda for prostate cancer
As a result of promising data from its Phase Ib/II KEYNOTE-365 trial, Merck has announced three new Phase III trials into the safety and efficacy of Keytruda (pembrolizumab) for patients with metastatic castration-resistant prostate cancer (mCRPC).
Passage Bio receives $115m in funding to address CNS diseases
Gene therapy company Passage Bio has launched in the US with $115.5m series A funding to develop AAV-delivered therapies for the treatment of rare monogenic central nervous system (CNS) disorders.
AstraZeneca hopes FDA breakthrough therapy can rise above a string of recent failures
A respiratory syncytial virus is a common pneumovirus that causes seasonal lung and respiratory tract infections across the globe.
SK Biopharmaceuticals-Arvelle partner on epilepsy drug cenobamate in Europe
South Korea-based SK Biopharmaceuticals and Swiss Arvelle Therapeutics have signed an exclusive licensing agreement to develop and commercialise SK Biopharmaceuticals’ cenobamate in Europe.
Erectile dysfunction: giving patients more choice and better treatments
Erectile dysfunction affects around 50% of men between 40 and 70 years old. Futura Medical is currently developing a topical gel product, named MED2005, as a new therapeutic approach for the condition. Can MED2005 add to the treatment choices in the erectile dysfunction space?
AbCellera and Novartis enter into multi-target partnership
Canada-based AbCellera has announced it has signed a multi-year, multi-target agreement with Novartis under which its antibody discovery technology will be leveraged by the Swiss pharma giant for up to ten clinically-relevant disease targets.
Decoy platelets could prevent clots and cancer spread
Researchers at the Wyss Institute at Harvard University have created ‘decoy’ platelets that could potentially reduce blood clots, as well as prevent cancer from spreading.
National Heart Month: how can you heal a broken heart?
February is National Heart Month in the US and the US, which focuses on raising awareness of heart disease. Often caused by emotional distress, takotsubo cardiomyopathy is a rare heart condition, sometimes called broken heart syndrome. Currently there are no approved treatments for the condition, but research is underway to remedy the situation.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.